Jane Wasman is President, International and General Counsel of Acorda Therapeutics since 2012, responsible for its internationalization strategy and operations. Additionally, she heads the company’s global strategic development process, including long-range planning. As Acorda’s General Counsel, Corporate Secretary and Chief Compliance Officer, she also manages its Legal/IP, Compliance and Quality departments. Acorda's Legal Department was named one of four "Best Legal Departments" in the U.S. by Corporate Counsel in 2013.
Previously, Ms. Wasman was with Schering-Plough Corporation from 1995-2004, holding various leadership positions, including Vice President and Associate General Counsel responsible for legal support for US pharmaceuticals operations; FDA regulatory matters; licensing and M&A; and, global R&D. She also served as Vice President, European Operations—Legal and then Vice President, International.
Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson. She also served as Associate Counsel to the U.S. Senate Committee on Veteran's Affairs. Ms. Wasman graduated Magna Cum Laude from Princeton University, and earned her J.D. from Harvard Law School.
Ms. Wasman has been on the Board of Directors, including its Executive Committee, of NY BIO since 2007, and on the Board of Biotie Therapies since 2016.